EFFICACY AND SAFETY OF BMS-2248 IN RENAL TRANSPLANT RECIPIENTS

BMS-2248 对肾移植受者的功效和安全性

• 批准号: 7605273
• 负责人: Jonathan S Bromberg
• 金额: $ 0.06万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605273
• 关键词: Allogenic; Allografting; Amendment; Antigens; BMS-224818; Binding; CD28 gene; CD80 gene; Class; Computer Retrieval of Information on Scientific Projects Database; Dose; Exposure to; Funding; Grant; Immune response; Institution; Kidney Transplantation; LEA29Y; Ligands; Maintenance; Organ Transplantation; Pharmaceutical Preparations; Research; Research Personnel; Resources; Safety; Signal Transduction; Source; T-Cell Activation; T-Cell Receptor; T-Lymphocyte; Therapeutic Agents; Transplant Recipients; United States National Institutes of Health; prevent; receptor; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This trial is studying the drug BMS-224818 which represents a new class of therapeutic agents that block the second signal required for T cell activation in an immune response. Safely controlling the recipient T cell response to a donor allograft is key to achieving normal function and long-term survival and function of a transplanted organ. Nanve T cells require signals through both the T cell receptor and a costimulatory receptor for full activation. CD28 is a key T cell costimulatory receptor molecule. BMS-224818 (LEA29Y) binds to CD80 and CD86, the ligands for CD28, thereby preventing full T cell activation and potentially inducing antigen-specific T cell hyporesponsiveness. Allogeneic transplant organ recipients can be treated with costimulation-blocking drugs like BMS-224818 prior to exposure to donor antigen, manipulating nanve T cell responses which are more susceptible to costimulation blockade than previously activated T cells. This is a two-year extension study (Amendment #3) of the main BMS study (GCO#00-1105) that is being conducted in the GCRC currently. If safety & efficacy are acceptable, maintenance dosing may be continued until year 2004.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该试验正在研究代表一种新的治疗剂的药物BMS-224818，该药物阻断了免疫反应中T细胞激活所需的第二个信号。 安全控制受体T细胞对供体同种异体移植的反应是实现正常功能和长期生存和移植器官的功能的关键。 Nanve T细胞需要通过T细胞受体和共刺激受体的信号才能充分激活。 CD28是一个关键的T细胞共刺激受体分子。 BMS-224818（LEA29Y）与CD80和CD86（用于CD28的配体）结合，从而防止全T细胞激活并潜在诱导抗原特异性T细胞细胞的低调。同种异体移植器官受体可以在暴露于供体抗原之前用诸如BMS-224818（BMS-224818）的结构刺激阻滞药物治疗，操纵NANVE T细胞反应，而Nanve T细胞反应比以前激活的T细胞更容易受到cot刺的阻滞。 这是当前在GCRC中进行的主要BMS研究（GCO＃00-1105）的两年扩展研究（修订＃3）。 如果可以接受安全和功效，则可以持续到2004年。